

Lawreen H Connors

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4632414/publications.pdf>

Version: 2024-02-01

95
papers

4,696
citations

101543

36
h-index

102487

66
g-index

96
all docs

96
docs citations

96
times ranked

3643
citing authors

#	ARTICLE	IF	CITATIONS
1	Tabulation of human transthyretin (TTR) variants, 2003. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2003, 10, 160-184.	3.0	449
2	Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress. <i>Circulation Research</i> , 2004, 94, 1008-1010.	4.5	358
3	Senile Systemic Amyloidosis Presenting With Heart Failure. <i>Archives of Internal Medicine</i> , 2005, 165, 1425.	3.8	315
4	Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38 β MAPK pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 4188-4193.	7.1	264
5	Infusion of Light Chains From Patients With Cardiac Amyloidosis Causes Diastolic Dysfunction in Isolated Mouse Hearts. <i>Circulation</i> , 2001, 104, 1594-1597.	1.6	233
6	Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. <i>Circulation</i> , 2016, 133, 282-290.	1.6	230
7	Amyloidogenic and Associated Proteins in Systemic Amyloidosis Proteome of Adipose Tissue. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 1570-1583.	3.8	134
8	Soft tissue, joint, and bone manifestations of AL amyloidosis: Clinical presentation, molecular features, and survival. <i>Arthritis and Rheumatism</i> , 2007, 56, 3858-3868.	6.7	130
9	Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. <i>American Heart Journal</i> , 2009, 158, 607-614.	2.7	129
10	Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. <i>Blood</i> , 2011, 118, 6610-6617.	1.4	127
11	Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 305, H95-H103.	3.2	123
12	Sequence Communication: Tabulation of transthyretin (TTR) variants as of 1/1/2000. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2000, 7, 54-69.	3.0	122
13	Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 62-67.	3.0	108
14	Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. <i>EMBO Molecular Medicine</i> , 2014, 6, 1493-1507.	6.9	106
15	Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. <i>ESC Heart Failure</i> , 2018, 5, 772-779.	3.1	89
16	The Critical Role of the Constant Region in Thermal Stability and Aggregation of Amyloidogenic Immunoglobulin Light Chain. <i>Biochemistry</i> , 2010, 49, 9848-9857.	2.5	79
17	AL-Base: a visual platform analysis tool for the study of amyloidogenic immunoglobulin light chain sequences. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 1-8.	3.0	70
18	Heterogeneity in Primary Structure, Post-Translational Modifications, and Germline Gene Usage of Nine Full-Length Amyloidogenic λ 1 Immunoglobulin Light Chains. <i>Biochemistry</i> , 2007, 46, 14259-14271.	2.5	61

#	ARTICLE	IF	CITATIONS
19	Characterization of Transthyretin Variants in Familial Transthyretin Amyloidosis by Mass Spectrometric Peptide Mapping and DNA Sequence Analysis. <i>Analytical Chemistry</i> , 2002, 74, 741-751.	6.5	57
20	Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. <i>Journal of Cardiac Failure</i> , 2020, 26, 753-759.	1.7	57
21	Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. <i>Basic Research in Cardiology</i> , 2013, 108, 378.	5.9	56
22	Blood Proteomic Profiling in Inherited (ATTRm) and Acquired (ATTRwt) Forms of Transthyretin-Associated Cardiac Amyloidosis. <i>Journal of Proteome Research</i> , 2017, 16, 1659-1668.	3.7	56
23	Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. <i>Circulation: Heart Failure</i> , 2018, 11, e004000.	3.9	55
24	Matrix Metalloproteinases and Their Tissue Inhibitors in Cardiac Amyloidosis. <i>Circulation: Heart Failure</i> , 2008, 1, 249-257.	3.9	53
25	Cellular Response of Cardiac Fibroblasts to Amyloidogenic Light Chains. <i>American Journal of Pathology</i> , 2005, 166, 197-208.	3.8	51
26	The Modulation of Transthyretin Tetramer Stability by Cysteine 10 Adducts and the Drug Diflunisal. <i>Journal of Biological Chemistry</i> , 2008, 283, 11887-11896.	3.4	51
27	Role of Glycosaminoglycan Sulfation in the Formation of Immunoglobulin Light Chain Amyloid Oligomers and Fibrils. <i>Journal of Biological Chemistry</i> , 2010, 285, 37672-37682.	3.4	49
28	Identification of S-sulfonation and S-thiolation of a novel transthyretin Phe33Cys variant from a patient diagnosed with familial transthyretin amyloidosis. <i>Protein Science</i> , 2003, 12, 1775-1785.	7.6	48
29	Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model. <i>JAMA Cardiology</i> , 2017, 2, 305.	6.1	48
30	Role of Endocytic Inhibitory Drugs on Internalization of Amyloidogenic Light Chains by Cardiac Fibroblasts. <i>American Journal of Pathology</i> , 2006, 169, 1939-1952.	3.8	47
31	Evidence for a Functional Role of the Molecular Chaperone Clusterin in Amyloidotic Cardiomyopathy. <i>American Journal of Pathology</i> , 2011, 178, 61-68.	3.8	46
32	Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. <i>Blood Cancer Journal</i> , 2021, 11, 139.	6.2	45
33	Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2005, 12, 210-215.	3.0	44
34	A simple screening test for variant transthyretins associated with familial transthyretin amyloidosis using isoelectric focusing. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1998, 1407, 185-192.	3.8	43
35	Induced Pluripotent Stem Cell Modeling of Multisystemic, Hereditary Transthyretin Amyloidosis. <i>Stem Cell Reports</i> , 2013, 1, 451-463.	4.8	42
36	Association of acquired von Willebrand syndrome with AL amyloidosis. <i>American Journal of Hematology</i> , 2007, 82, 363-367.	4.1	39

#	ARTICLE	IF	CITATIONS
37	Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2008, 15, 255-261.	3.0	39
38	Betabellins 15D and 16D, de Novo Designed \hat{I}^2 -Sandwich Proteins That Have Amyloidogenic Properties. <i>Journal of Structural Biology</i> , 2000, 130, 363-370.	2.8	36
39	Homozygosity for the V122I Mutation in Transthyretin Is Associated with Earlier Onset of Cardiac Amyloidosis in the African American Population in the Seventh Decade of Life. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 68-74.	2.8	35
40	Biophysical analysis of normal transthyretin: Implications for fibril formation in senile systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2001, 8, 75-83.	3.0	31
41	Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. <i>Scientific Reports</i> , 2019, 9, 8552.	3.3	31
42	Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E6428-E6436.	7.1	26
43	Patient outcomes in light chain (AL) amyloidosis: The clock is ticking from symptoms to diagnosis. <i>European Journal of Haematology</i> , 2020, 105, 495-501.	2.2	26
44	Circulating Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Cardiac Amyloidosis. <i>Journal of the American Heart Association</i> , 2013, 2, e005868.	3.7	25
45	Expression, purification, and in vitro cysteine-10 modification of native sequence recombinant human transthyretin. <i>Protein Expression and Purification</i> , 2007, 53, 370-377.	1.3	24
46	Thermodynamic Stability of a \hat{I}^{H} Immunoglobulin Light Chain: Relevance to Multiple Myeloma. <i>Biophysical Journal</i> , 2005, 88, 4232-4242.	0.5	21
47	Cooperative Stabilization of Transthyretin by Clusterin and Diflunisal. <i>Biochemistry</i> , 2015, 54, 268-278.	2.5	21
48	Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. <i>Blood Cancer Journal</i> , 2020, 10, 118.	6.2	21
49	Transthyretin Aggregate-Specific Antibodies Recognize Cryptic Epitopes on Patient-Derived Amyloid Fibrils. <i>Rejuvenation Research</i> , 2014, 17, 97-104.	1.8	20
50	Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt). <i>Human Genetics</i> , 2015, 134, 111-121.	3.8	20
51	A new lysozyme tyr54asn mutation causing amyloidosis in a family of Swedish ancestry with gastrointestinal symptoms. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2012, 19, 182-185.	3.0	19
52	A new transthyretin variant (Ser2 sn) associated with familial amyloidosis in a Portuguese patient. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1999, 6, 114-118.	3.0	18
53	Identification of a novel transthyretin Thr59Lys/Arg104His. A case of compound heterozygosity in a Chinese patient diagnosed with familial transthyretin amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 134-140.	3.0	18
54	Hereditary Renal Amyloidosis Associated With a Novel Apolipoprotein A-II Variant. <i>Kidney International Reports</i> , 2017, 2, 1223-1232.	0.8	17

#	ARTICLE	IF	CITATIONS
55	Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: A case report with literature review. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2009, 16, 103-107.	3.0	16
56	A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2004, 11, 61-66.	3.0	14
57	Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 120-121.	3.0	14
58	A new era of amyloidosis: the trends at a major US referral centre. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 192-196.	3.0	14
59	Use of Ventilatory Efficiency Slope as a Marker for Increased Mortality in Wild-Type Transthyretin Cardiac Amyloidosis. <i>American Journal of Cardiology</i> , 2019, 124, 122-130.	1.6	14
60	Oxidative post-translational modifications of an amyloidogenic immunoglobulin light chain protein. <i>International Journal of Mass Spectrometry</i> , 2017, 416, 71-79.	1.5	13
61	A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and <i>in vitro</i> testing of novel therapeutics. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018, 25, 148-155.	3.0	13
62	Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 71-78.	3.0	13
63	Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease. <i>Stem Cell Reports</i> , 2020, 15, 515-528.	4.8	12
64	Detection of high-molecular-weight amyloid serum protein complexes using biological on-line tracer sedimentation. <i>Analytical Biochemistry</i> , 2012, 425, 151-156.	2.4	11
65	Transthyretin amyloidosis associated with a novel variant (Trp41Leu) presenting with vitreous opacities. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2002, 9, 263-267.	3.0	10
66	A new transthyretin variant (Glu61Gly) associated with cardiomyopathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2007, 14, 65-71.	3.0	9
67	Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 253-255.	3.0	9
68	Structural Characterization of Cardiac Ex Vivo Transthyretin Amyloid: Insight into the Transthyretin Misfolding Pathway In Vivo. <i>Biochemistry</i> , 2020, 59, 1800-1803.	2.5	9
69	A Conservative Point Mutation in a Dynamic Antigen-binding Loop of Human Immunoglobulin λ 6 Light Chain Promotes Pathologic Amyloid Formation. <i>Journal of Molecular Biology</i> , 2021, 433, 167310.	4.2	9
70	Dysregulation of miRNAs in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2011, 18, 128-135.	3.0	8
71	Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2016, 23, 214-220.	3.0	8
72	Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, 29, 184-189.	3.0	8

#	ARTICLE	IF	CITATIONS
73	<i>In vitro</i> co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 115-122.	3.0	6
74	Serum Proteomic Variability Associated with Clinical Phenotype in Familial Transthyretin Amyloidosis (ATTRm). <i>Journal of Proteome Research</i> , 2017, 16, 4104-4112.	3.7	5
75	Glycosylation of Serum Clusterin in Wild-Type Transthyretin-Associated (ATTRwt) Amyloidosis: A Study of Disease-Associated Compositional Features Using Mass Spectrometry Analyses. <i>Biochemistry</i> , 2020, 59, 4367-4378.	2.5	5
76	Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis. <i>Kidney Medicine</i> , 2022, 4, 100427.	2.0	4
77	Vertebral compression fractures as the initial presentation of AL amyloidosis: case series and review of literature. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2015, 22, 156-162.	3.0	2
78	A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis. <i>Blood</i> , 2021, 138, 155-155.	1.4	2
79	A novel substitution of proline (P32L) destabilises β 2-microglobulin inducing hereditary systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, , 1-8.	3.0	2
80	Effect of diflunisal on clusterin levels in ATTRwt amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 49-50.	3.0	1
81	Structural studies of serum clusterin in ATTRwt amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 51-52.	3.0	1
82	Bone Marrow Biopsy and Its Utility in the Diagnosis of AL Amyloidosis. <i>Current Clinical Pathology</i> , 2015, , 343-353.	0.0	1
83	Familial wild-type transthyretin cardiomyopathy. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017, 24, 91-92.	3.0	0
84	Analysis of the non-coding rs3764479 mutation in the proximal promoter of the transthyretin gene. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 83-84.	3.0	0
85	Association of Acquired Von Willebrand Syndrome with Primary (AL) Amyloidosis.. <i>Blood</i> , 2005, 106, 4078-4078.	1.4	0
86	Expression of Human Amyloidogenic Immunoglobulin Light Chains in Mice Leads to Organ Toxicity.. <i>Blood</i> , 2005, 106, 3412-3412.	1.4	0
87	Human Amyloidogenic Light Chains Alter Cardiomyocyte Signaling Through Disruption of Heparan Sulfate Proteoglycan (HSPG) Complex. <i>FASEB Journal</i> , 2006, 20, A935.	0.5	0
88	Dysregulation of miRNAs In AL Amyloidosis. <i>Blood</i> , 2010, 116, 4648-4648.	1.4	0
89	Bone Marrow Biopsy and Its Utility in the Diagnosis of AL Amyloidosis and Other Plasma Cell Dyscrasias. , 2012, , 283-290.		0
90	Transthyretin Stabilizers: Preventing Amyloidosis. <i>FASEB Journal</i> , 2012, 26, .	0.5	0

#	ARTICLE	IF	CITATIONS
91	The circulating molecular chaperone clusterin interacts with amyloidogenic transthyretin oligomers and modulates amyloid formation. FASEB Journal, 2013, 27, 996.9.	0.5	0
92	Single nucleotide polymorphisms in the 3' untranslated and near gene regions of transthyretin may play a role in senile systemic amyloidosis. FASEB Journal, 2013, 27, 874.30.	0.5	0
93	Heavy/Light Chain Quantification Identifies Clonal Plasma Cell Disease in Patients with AL Amyloidosis and Normal Serum Free Light Chain Ratio. Blood, 2015, 126, 2956-2956.	1.4	0
94	The Changing Face of Amyloidosis Referrals at a Tertiary Center over the Past 3 Decades. Blood, 2018, 132, 5536-5536.	1.4	0
95	Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes. Blood, 2020, 136, 51-51.	1.4	0